Variant forms of urate oxidase and use thereof

• US 10,731,139 B2
• Filed: 11/28/2018
• Issued: 08/04/2020
• Est. Priority Date: 04/11/2005
• Status: Active Grant

• Current Assignee: Horizon Therapeutics USA, Inc. (Amgen Inc.)
• Original Assignee: Horizon Pharma Rheumatology LLC (Amgen Inc.)
• Inventors: Hartman, Jacob, Mendelovitz, Simona
• Primary Examiner(s): Ha, Julie
• Application Number:
  US16/202,743
• Publication Number:
  US 20190316097A1
• Time in Patent Office: 615 Days
• Field of Search: 435188191, 43525233, 4353201, 424 943, 424 944, 536 232
• CPC Class Codes: A61K 38/44 Oxidoreductases (1)
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 19/06 Antigout agents, e.g. antihyperuricemic or uricosuric agents
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 9/0046 with oxygen as acceptor (1.7.3)
• CPC Class Codes: C12N 9/0048 Uricase (1.7.3.3)
• CPC Class Codes: C12Y 107/03003 Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase

Abstract

Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.

Claims

1. A method of reducing elevated uric acid levels in a subject in need thereof, comprising intravenously administering a pharmaceutical composition comprising:

a conjugate comprising a tetrameric uricase and polyethylene glycol (PEG), wherein the uricase comprises the amino acid sequence of SEQ ID NO;

8; and

phosphate buffered saline (PBS).

2. The method of claim 1, wherein the PEG is monomethoxyPEG (mPEG).

3. The method of claim 2, wherein the mPEG has a molecular weight between 5 kDa and 20 kDa.

4. The method of claim 3, wherein the mPEG has a molecular weight of about 10 kDa.

5. The method of claim 4, wherein the mPEG is covalently attached to a lysine residue of the uricase.

6. The method of claim 4, wherein the conjugate comprises about 2-12 mPEG molecules per uricase monomer.

7. The method of claim 6, wherein the pharmaceutical composition comprises 8 mg of the uricase.

8. The method of claim 1, wherein the pharmaceutical composition comprises 8 mg of the uricase per mL of solution.

9. The method of claim 8, wherein the pharmaceutical composition is diluted into 250 mL of saline solution for administration.

10. The method of claim 1, wherein the pharmaceutical composition is administered at a dosage of 8 mg of the uricase.

11. The method of claim 1, wherein the pharmaceutical composition is administered at a dosage of 8 mg of the uricase every two weeks.

12. The method of claim 1, wherein the pharmaceutical composition is administered over a 120-minute period.

13. The method of claim 12, wherein the uric acid level is reduced in the plasma of the subject.

14. The method of claim 13, wherein the plasma uric acid level is lowered to 6.0 mg/dl or less.

15. The method of claim 13, wherein the subject has a plasma uric acid level of 6.0 mg/dl or less for at least 80% of a treatment period.

16. The method of claim 11, wherein the subject receives an antihistamine or a corticosteroid prior to the administration of the conjugate.

17. The method of claim 11, wherein the subject receives acetaminophen prior to the administration of the conjugate.

18. The method of claim 11, wherein the subject receives a nonsteroidal anti-inflammatory drug (NSAID) prior to the administration of the conjugate.

19. The method of claim 11, wherein the subject is an adult subject.

20. The method of claim 11, wherein the subject is suffering from gout.

21. The method of claim 11, wherein the subject is suffering from gout that is refractory to conventional therapy.